Do Options Traders Know Something About Insulet Stock We Don't?
Investors need to pay close attention to PODD stock based on the movements in the options market lately.
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.
Why Insulet ( PODD ) Might be Well Poised for a Surge
Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stocks to Buy for Nov. 13
FLEX, PODD and PRAA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Nov. 13, 2025.
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.
New Strong Buy Stocks for Nov. 13: PODD, PRAA, and More
PFBC, WFRD, PODD, PRAA and ALX have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 13, 2025.
3 Top Momentum Stocks to Buy as U.S. Shutdown Nears End
The Senate's move to end the record shutdown lifts Wall Street, spotlighting momentum stocks like Insulet, Celestica and Innodata.
Decoding DexCom's Options Activity: What's the Big Picture? - DexCom ( NASDAQ:DXCM )
Whales with a lot of money to spend have taken a noticeably bearish stance on DexCom. Looking at options history for DexCom ( NASDAQ:DXCM ) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish ...
Insulet ( PODD ) Upgraded to Strong Buy: Here's What You Should Know
Insulet (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Reasons Why Growth Investors Shouldn't Overlook Insulet ( PODD )
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insulet ( PODD ) Q3 Earnings and Revenues Beat Estimates
Insulet (PODD) delivered earnings and revenue surprises of +9.73% and +4.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Insulet, Uber And A Financial Stock On CNBC's 'Final Trades' - Apollo Asset Management ( NYSE:APO ) , Insulet ( NASDAQ:PODD )
On CNBC's "Halftime Report Final Trades," Joseph Terranova, senior managing director at Virtus Investment Partners, named Insulet Corporation ( NASDAQ:PODD ) , a maker of wearable devices for insulin management, as his final trade.
Ahead of Insulet ( PODD ) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Can Strength in Rental Business Drive INFU Stock Before Q3 Earnings?
InfuSystem eyes third-quarter 2025 gains as rental contracts and ERP upgrades boost margins across Patient Services and Device Solutions.
Peering Into Insulet Corp's Recent Short Interest - Insulet ( NASDAQ:PODD )
Insulet Corp's ( NYSE:PODD ) short interest as a percent of float has risen 10.48% since its last report. According to exchange reported data, there are now 1.61 million shares sold short, which is 3.48% of all regular shares that are available for trading.
Here's Why Insulet ( PODD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash
Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit.
Here's Why Insulet ( PODD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash
Align Technology jumps 15% after Q3 earnings and revenues beat estimates, though steep margin declines weigh on results.
$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet ( NASDAQ:PODD ) has outperformed the market over the past 15 years by 10.68% on an annualized basis producing an average annual return of 22.81%. Currently, Insulet has a market capitalization of $22.26 billion.
Insulet ( PODD ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash
Chemed's Q3 miss sends shares lower as shrinking margins and weaker EPS overshadow steady revenue gains from VITAS and Roto-Rooter.
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down.
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines
Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs
TMO delivers robust Q3 results, fueled by margin growth, new launches and AI-focused strategic initiatives.
Here's How Much You Would Have Made Owning Insulet Stock In The Last 10 Years - Insulet ( NASDAQ:PODD )
Insulet ( NASDAQ:PODD ) has outperformed the market over the past 10 years by 14.71% on an annualized basis producing an average annual return of 27.22%. Currently, Insulet has a market capitalization of $23.16 billion.
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
Neogen Q1 Earnings Miss Estimates, Revenues Beat, Stock Climbs
NEOG's Q1 earnings decline 42.9% year over year, while revenues of $209.2 million top the consensus mark.
Is Insulet ( PODD ) a Solid Growth Stock? 3 Reasons to Think "Yes"
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Price Over Earnings Overview: Insulet - Insulet ( NASDAQ:PODD )
Looking into the current session, Insulet Inc. ( NASDAQ:PODD ) shares are trading at $306.78, after a 1.24% drop. Over the past month, the stock fell by 11.06%, but over the past year, it actually spiked by 31.87%.
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet ( NASDAQ: PODD ) has outperformed the market over the past 15 years by 10.02% on an annualized basis producing an average annual return of 22.35%. Currently, Insulet has a market capitalization of $21.87 billion.
Why Insulet ( PODD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Here's How Much $100 Invested In Insulet 10 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 10 years by 14.5% on an annualized basis producing an average annual return of 27.65%. Currently, Insulet has a market capitalization of $23.29 billion.
Spotlight on DexCom: Analyzing the Surge in Options Activity - DexCom ( NASDAQ:DXCM )
Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Here's Why Insulet ( PODD ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Insulet ( PODD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 11.51% on an annualized basis producing an average annual return of 23.94%. Currently, Insulet has a market capitalization of $24.22 billion.
Here's Why Insulet ( PODD ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Insulet ( PODD ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Gains 77.2% in a Year: What's Driving the Rally?
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Cisco, Rocket Companies, Insulet And More On CNBC's 'Final Trades' - Cisco Systems ( NASDAQ:CSCO ) , iShares Expanded Tech-Software Sector ETF ( BATS:IGV )
Liz Young Thomas said iShares Expanded Tech-Software Sector ETF ( NYSE: IGV ) is way under-loved. Jim Lebenthal says Cisco pulled back around 8% after earnings. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Here's How Much You Would Have Made Owning Insulet Stock In The Last 15 Years - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 10.41% on an annualized basis producing an average annual return of 23.21%. Currently, Insulet has a market capitalization of $22.62 billion.
Is the Market Bullish or Bearish on Insulet? - Insulet ( NASDAQ:PODD )
Insulet's PODD short percent of float has fallen 17.43% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 3.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.58 days to cover their ...
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
